Ardelyx, Inc. - Common Stock (OQ:ARDX)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

May 21, 2024 08:02 am ET

Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional...

May 16, 2024 08:01 am ET

Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)

May 14, 2024 04:02 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

May 07, 2024 08:01 am ET

Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference

May 02, 2024 04:02 pm ET

Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update

May 01, 2024 08:00 am ET

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings

Apr 18, 2024 08:00 am ET

Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024

Mar 28, 2024 04:05 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

Mar 25, 2024 08:00 am ET

Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy

Mar 12, 2024 04:35 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

Feb 27, 2024 08:00 am ET

Ardelyx to Participate at the Cowen 44th Annual Health Care Conference

Feb 23, 2024 08:31 am ET

Thinking about buying stock in Intuitive Machines, OPKO Health, Ardelyx, AXT Inc, or Clearmind Medicine?

NEW YORK, Feb. 23, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LUNR, OPK, ARDX, AXTI, and CMND.

Feb 22, 2024 04:01 pm ET

Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 01, 2024 08:00 am ET

Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

Jan 29, 2024 08:31 am ET

Thinking about buying stock in Macy's, Ardelyx, SoFi Technologies, Panbela Therapeutics, or Himax Technologies?

NEW YORK, Jan. 29, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for M, ARDX, SOFI, PBLA, and HIMX.

Jan 12, 2024 07:56 am ET

Ardelyx, Inc. Reports Employment Inducement Grants

Jan 09, 2024 08:31 am ET

Thinking about buying stock in Angion Biomedica, Ardelyx, AMC Entertainment, Applied Therapeutics, or Wisekey International Holding ?

NEW YORK, Jan. 9, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ELTX, ARDX, AMC, APLT, and WKEY.

Jan 08, 2024 08:00 am ET

Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities

Jan 03, 2024 08:03 am ET

Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8

Dec 21, 2023 08:31 am ET

Thinking about buying stock in Annexin Pharmaceuticals, Ardelyx, Fusion Pharmaceuticals, Aurora Technology Acquisition, or Terran Orbital?

NEW YORK, Dec. 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ANNX, ARDX, FUSN, ATAK, and LLAP.

Dec 20, 2023 08:00 am ET

Ardelyx, Inc. Reports Employment Inducement Grants

Dec 12, 2023 08:31 am ET

Thinking about buying stock in Crispr Therapeutics, Ardelyx, ADC Therapeutics, Acurx Pharmaceuticals, or Sphere 3D?

NEW YORK, Dec. 12, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRSP, ARDX, ADCT, ACXP, and ANY.

Nov 28, 2023 08:31 am ET

Thinking about buying stock in Ardelyx, Autolus Therapeutics, SMX (Security Matters) PLC, Hudson Pacific Properties, or Dharma Polimetal?

NEW YORK, Nov. 28, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARDX, AUTL, SMX, HPP, and DRMA.

Nov 27, 2023 08:31 am ET

Thinking about buying stock in Perfect Corp, UP Fintech, Theseus Pharmaceuticals, Reliance Sekuritas Indonesia, or Ardelyx?

NEW YORK, Nov. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PERF, TIGR, THRX, RELI, and ARDX.

Nov 21, 2023 04:02 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

Nov 21, 2023 08:01 am ET

Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference

Nov 15, 2023 04:02 pm ET

XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia

Nov 13, 2023 04:02 pm ET

Ardelyx Announces Departure of Board Member

Nov 10, 2023 08:05 am ET

Ardelyx to Participate at the Jefferies London Healthcare Conference

Nov 06, 2023 08:00 am ET

Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States

Nov 03, 2023 08:00 am ET

Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023

Nov 02, 2023 02:58 pm ET

SHAREHOLDER ALERT: Morris Kandinov Investigating ARDX, LESL, ENVX, and FATE; Shareholders are Encouraged to Contact the Firm

National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Ardelyx, Inc., Leslie’s, Inc., Enovix Corporation, and Fate Therapeutics, Inc. If you are a current owner of shares of any of these stocks,...

Oct 31, 2023 07:00 am ET

Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance

Oct 30, 2023 05:42 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

Oct 25, 2023 09:31 am ET

Thinking about buying stock in VinFast Auto, Ardelyx, Harpoon Therapeutics, Mind Technology, or Ault Alliance?

NEW YORK, Oct. 25, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VFS, ARDX, HARP, MIND, and AULT.

Oct 24, 2023 09:31 am ET

Thinking about buying stock in VinFast Auto, Ardelyx, Harpoon Therapeutics, Mind Technology, or Ault Alliance?

NEW YORK, Oct. 24, 2023 /PRNewswire/ --InvestorsObserver issues critical PriceWatch Alerts for VFS, ARDX, HARP, MIND, and AULT.

Oct 23, 2023 08:07 am ET

Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023

Oct 20, 2023 09:31 am ET

Thinking about buying stock in Ardelyx, Rivian Automotive, Femasys, Lucid Group, or Outlook Therapeutics?

NEW YORK, Oct. 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARDX, RIVN, FEMY, LCID, and OTLK.

Oct 19, 2023 09:31 am ET

Thinking about buying stock in Ardelyx, RVL Pharmaceuticals, Wheeler Real Estate Investment Trust, Troika Media Group, or AT&T?

NEW YORK, Oct. 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARDX, RVLP, WHLR, TRKA, and T.

Oct 18, 2023 04:02 pm ET

Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023

Oct 18, 2023 09:31 am ET

Thinking about buying stock in Tempest Therapeutics, VinFast Auto, AGNC Investment, Ardelyx, or Viking Therapeutics?

NEW YORK, Oct. 18, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TPST, VFS, AGNC, ARDX, and VKTX.

Oct 17, 2023 07:23 pm ET

Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital

Oct 17, 2023 07:01 pm ET

FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor

Oct 13, 2023 08:00 am ET

Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA

Oct 04, 2023 08:00 am ET

Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023

Sep 28, 2023 08:02 am ET

Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

Sep 25, 2023 04:15 am ET

Tenapanor for Hyperphosphatemia Approved in Japan

Sep 11, 2023 08:00 am ET

Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023

Sep 08, 2023 08:00 am ET

Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 07, 2023 08:00 am ET

Ardelyx, Inc. Reports Employment Inducement Grants

Aug 02, 2023 07:00 am ET

Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance

Jul 27, 2023 04:05 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

Jul 27, 2023 09:31 am ET

Thinking about buying stock in Joby Aviation, Aurora Innovation, Terawulf, Ardelyx, or Immunic?

NEW YORK, July 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JOBY, AUR, WULF, ARDX, and IMUX.

Jul 26, 2023 07:55 am ET

Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023

Jul 20, 2023 04:05 pm ET

Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference

Jul 13, 2023 08:00 am ET

Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China

Jul 12, 2023 09:31 am ET

Thinking about buying stock in Lucid Group, Aurora Innovation, Enphase Energy, 89bio, or Ardelyx?

NEW YORK, July 12, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LCID, AUR, ENPH, ETNB, and ARDX.

Jun 29, 2023 04:09 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

Jun 05, 2023 08:00 am ET

Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase

May 31, 2023 08:00 am ET

Ardelyx to Present at the Jefferies 2023 Healthcare Conference

May 23, 2023 04:05 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

May 17, 2023 07:30 am ET

Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)

May 15, 2023 04:05 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

May 09, 2023 08:00 am ET

Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

May 03, 2023 04:02 pm ET

Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update

May 01, 2023 08:00 am ET

Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference

Apr 26, 2023 08:00 am ET

Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023

Apr 18, 2023 08:00 am ET

Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)

Apr 13, 2023 04:05 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

Apr 12, 2023 04:05 pm ET

Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings

Mar 02, 2023 04:02 pm ET

Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Feb 28, 2023 08:00 am ET

Ardelyx Publishes First Environmental, Social and Governance (ESG) Report

Feb 27, 2023 08:15 am ET

Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference

Feb 23, 2023 08:00 am ET

Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023

Feb 02, 2023 03:20 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., Feb. 2, 2023 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on January 27, 2023, the compensation committee of the company's board of directors granted 23 new non-executive employees options to purchase an aggregate of 614,064 shares of the company's common stock, and an aggregate of 236,333 Restricted Stock Units (RSUs). Each stock option has an exercise price per share equal to $2.85 pe

Jan 19, 2023 09:57 am ET

Thinking about buying stock in Neurosense Therapeutics, American Airlines, General Electric, Pfizer, or Ardelyx?

NEW YORK, Jan. 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NRSN, AAL, GE, PFE, and ARDX.

Dec 30, 2022 09:58 am ET

Thinking about buying stock in Mullen Automotive, Hoth Therapeutics, Futu Holdings, Shaw Communications, or Ardelyx?

NEW YORK, Dec. 30, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MULN, HOTH, FUTU, SJR, and ARDX.

Dec 29, 2022 09:58 am ET

Thinking about buying stock in Esports Entertainment, Ardelyx, Gaotu Techedu, Hoth Therapeutics, or IQIYI?

NEW YORK, Dec. 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GMBL, ARDX, GOTU, HOTH, and IQ.

Dec 29, 2022 06:00 am ET

FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)

Office of New Drugs directs the Division of Cardiology and Nephrology to work with Ardelyx to develop a label to support the commercialization of XPHOZAH; Ardelyx to resubmit NDA in the first half of 2023

Dec 23, 2022 04:58 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., Dec. 23, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on December 16, 2022, the compensation committee of the company's board of directors granted 17 new non-executive employees options to purchase an aggregate of 271,735 shares of the company's common stock, and an aggregate of 123,375 Restricted Stock Units (RSUs). Each stock option has an exercise price per share equal to $1.96 p

Dec 23, 2022 09:41 am ET

Thinking about buying stock in Core Scientific, DBV Technologies, Gaotu Techedu, New Oriental Education, or Ardelyx?

NEW YORK, Dec. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CORZ, DBVT, GOTU, EDU, and ARDX.

Dec 16, 2022 06:51 pm ET

Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

WALTHAM, Mass., Dec. 16, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, provided an update regarding the appeal to the Complete Response Letter for the New Drug Application for XPHOZAH (tenapanor).

Nov 22, 2022 07:00 am ET

Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference

WALTHAM, Mass., Nov. 22, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that management will participate in a fireside discussion at the 34th Annual Piper Sandler Healthcare Conference on Thursday, December 1, 2022, at 10:00 a.m. ET in New York City.

Nov 16, 2022 05:29 pm ET

Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysi

The Advisory Committee voted 9:4 in favor of XPHOZAH as a monotherapy and 10:2 in favor of XPHOZAH in combination with phosphate binders

Nov 16, 2022 08:00 am ET

Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

WALTHAM, Mass., Nov. 16, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Nasdaq has halted trading of the Company's common stock.

Nov 14, 2022 09:37 am ET

Thinking about buying stock in Canopy Growth Corp, Starbucks, Opiant Pharmaceuticals, Phunware, or Ardelyx?

NEW YORK, Nov. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, SBUX, OPNT, PHUN, and ARDX.

Nov 04, 2022 01:39 pm ET

National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels

Majority of survey respondents call for new treatments to help manage phosphorus levels

Nov 03, 2022 04:01 pm ET

Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Conference call scheduled for 4:30 p.m. Eastern Time today

Nov 03, 2022 10:00 am ET

Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphoru

XPHOZAH monotherapy lowers serum phosphorus with early responders maintaining response with continued treatment

Nov 02, 2022 04:01 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., Nov. 2, 2022 /PRNewswire/ --Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on October 26, 2022, the compensation committee of the company's board of directors granted three new non-executive employees options to purchase an aggregate of 127,907 shares of the company's common stock, and an aggregate of 31,875 Restricted Stock Units (RSUs). Each stock option has an exercise price per share equal to $1.40 pe

Oct 31, 2022 08:00 am ET

Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan

Ardelyx to receive an aggregate of $35 million in milestone payments and payments associated with the recent amendment of the license agreement

Oct 27, 2022 08:00 am ET

Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022

- Conference call scheduled for 4:30 p.m. Eastern Time

Oct 24, 2022 08:00 am ET

Ardelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting

WALTHAM, Mass., Oct. 24, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that post-hoc analyses from its Phase 3 T3MPO trials will be presented in two posters at the 2022 American College of Gastroenterology Annual Scientific Meeting (ACG 2022) taking place in Charlotte, North Carolina from October 21-26, 2022 and virtually.

Oct 20, 2022 04:01 pm ET

Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022

WALTHAM, Mass., Oct. 20, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced three posters will be presented at the American Society of Nephrology (ASN) Kidney Week 2022 to be held November 3-6, 2022, in Orlando, Florida. XPHOZAH (tenapanor), discovered and developed by Ardelyx, is an investigational first-in-class phosphate absorption inhibitor (PAI) for the control of serum phosphorus in adult patients with c

Sep 30, 2022 04:01 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., Sept. 30, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on September 26, 2022, the compensation committee of the company's board of directors granted four new non-executive employees options to purchase an aggregate of 56,250 shares of the company's common stock, and an aggregate of 26,000 Restricted Stock Units (RSUs). Each stock option has an exercise price per share equal to $1.13

Sep 30, 2022 08:33 am ET

Thinking about buying stock in First Wave BioPharma, Amylyx Pharmaceuticals, IonQ, Arcimoto, or Ardelyx?

NEW YORK, Sept. 30, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FWBI, AMLX, IONQ, FUV, and ARDX.

Sep 08, 2022 08:41 am ET

Thinking about buying stock in Amylyx Pharmaceuticals, Asana, Revance Therapeutics, Ardelyx, or GameStop?

NEW YORK, Sept. 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMLX, ASAN, RVNC, ARDX, and GME.

Sep 07, 2022 09:31 am ET

Thinking about buying stock in Aquestive Therapeutics, Alaunos Therapeutics, Ardelyx, IVERIC Bio, or Nio?

NEW YORK, Sept. 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AQST, TCRT, ARDX, ISEE, and NIO.

Sep 06, 2022 08:00 am ET

Ardelyx to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 6, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences:

Aug 04, 2022 04:01 pm ET

Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Conference call scheduled for 4:30 p.m. Eastern Time today

Aug 02, 2022 08:00 am ET

Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference

WALTHAM, Mass., Aug. 2, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a virtual fireside chat at the 2022 Wedbush PacGrow Healthcare Conference. The fireside chat will take place on Tuesday, August 9, 2022, at 4:40 p.m. ET.

Jul 28, 2022 08:00 am ET

Ardelyx to Report Second Quarter 2022 Financial Results on August 4, 2022

— Conference call scheduled for 4:30 p.m. Eastern Time

Jun 30, 2022 08:00 am ET

Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners

HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA® in the United States in exchange for future hyperphosphatemia royalty payments from Ardelyx Japanese collaboration partner

Jun 21, 2022 08:00 am ET

Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022

WALTHAM, Mass. , June 21, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has informed the company that a meeting of the Cardiovascular and Renal Drugs Advisory Committee (Advisory Committee) is tentatively scheduled for November 16, 2022. The Advisory Committee will discuss the company's New Drug Application (NDA) for XPHOZAH for the control of serum phospho

Jun 03, 2022 08:00 am ET

Ardelyx to Present at the Jefferies 2022 Healthcare Conference

WALTHAM, Mass., June 3, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022, at 8:30 a.m. ET in New York City.

May 24, 2022 04:01 pm ET

Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

Three poster presentations continue to highlight the safety and efficacy of IBSRELA based on data from two Phase 3 trials in adults with irritable bowel syndrome with constipation (IBS-C)

May 17, 2022 04:01 pm ET

Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022

WALTHAM, Mass., May 17, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting the efficacy and safety of IBSRELA will be presented in three posters at the 2022 Digestive Disease Week Conference (DDW 2022) to be held May 21-24, 2022, in San Diego, California and virtually.

May 16, 2022 04:01 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., May 16, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on May 9, 2022, the compensation committee of the company's board of directors granted three new non-executive employees options to purchase an aggregate of 26,953 shares of the company's common stock, and granted an aggregate of 29,250 Restricted Stock Units (RSUs) to six new non-executive employees. Each stock option has an exerc

May 05, 2022 04:01 pm ET

Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights

Conference Call Scheduled for 4:30 PM Eastern Time Today

May 02, 2022 04:01 pm ET

Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of...

Apr 28, 2022 08:00 am ET

Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022

— Conference Call scheduled for 4:30 PM Eastern Time

Apr 25, 2022 08:30 am ET

Thinking about buying stock in ToughBuilt Industries, Ardelyx, Nkarta, Erytech Pharma, or BigBear.ai?

NEW YORK, April 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TBLT, ARDX, NKTX, ERYP, and BBAI.

Apr 25, 2022 07:00 am ET

Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)

- Ardelyx welcomes the opportunity for the company, patients, and practicing nephrologists to speak to clinically meaningful results in treating hyperphosphatemia -

Apr 13, 2022 03:34 pm ET

Lifshitz Law Firm, P.C. Announces Investigations of Ardelyx Inc. (NASDAQGM: ARDX), Hyzon Motors Inc. (NASDAQ: HYZN), View, Inc. (NASDAQGM: VIEW). and Zymergen Inc. (NASDAQGS: ZY)

Ardelyx Inc. (NASDAQGM: ARDX) Lifshitz Law PLLC announces that a class action complaint was filed on behalf of shareholders of ARDX alleging that Defendants made materially false and misleading statements regarding tenapanor and the likelihood...

Apr 12, 2022 04:26 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., April 12, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on April 5, 2022, the compensation committee of the company's board of directors granted five new non-executive employees options to purchase an aggregate of 68,797 shares of the company's common stock, and an aggregate of 33,450 Restricted Stock Units (RSUs). Each stock option has an exercise price per share equal to $1.11 per s

Apr 11, 2022 07:00 am ET

Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor

WALTHAM, Mass., April 11, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that it has reached an agreement with its Japanese collaboration partner, Kyowa Kirin Co. Ltd., to amend the license agreement, originally executed in 2017, that grants to Kyowa Kirin exclusive rights to develop and commercialize Ardelyx's tenapanor for the treatment of cardiorenal diseases, including hyperphosphatemia, in Japan.

Apr 07, 2022 08:00 am ET

Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings

Four posters support the important role that XPHOZAH, with its novel phosphate blocking mechanism, could potentially play in the treatment of hyperphosphatemiaXPHOZAH alone or in combination with binders, increased the proportion of patients able to achieve target phosphorus levels Patients reported improved experience with phosphate management routine during OPTIMIZE study, compared to previous phosphate lowering therapies Responder analysis from PHREEDOM demonstrates 77% of patients experienced phosphate lowering with XPHOZAH, with 41% of responders achieving a > 2 mg/dL decreaseWALTHAM

Apr 04, 2022 08:00 am ET

Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults

IBSRELA®(tenapanor) is the First and Only NHE3 Inhibitor FDA Approved for the Treatment of IBS-C in AdultsFirst Novel Mechanism Therapy to Treat IBS-C in a DecadeProduct Now AvailableWALTHAM, Mass., April 4, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced the launch of IBSRELA, the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is th

Apr 01, 2022 09:00 pm ET

ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Mar 09, 2022 03:01 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., March 9, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on March 4, 2022, the compensation committee of the company's board of directors granted ten new non-executive employees options to purchase an aggregate of 105,470 shares of the company's common stock, and granted an aggregate of 71,250 Restricted Stock Units (RSUs) to eleven new non-executive employees. Each stock option has an

Mar 04, 2022 09:00 pm ET

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Ardelyx, BioMarin, Chegg, and ChemoCentryx on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Ardelyx, Inc. (NASDAQ: ARDX), BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN), Chegg, Inc. (NYSE: CHGG), and...

Mar 02, 2022 05:55 pm ET

Ardelyx to Participate at the Cowen 42nd Annual Health Care Conference

WALTHAM, Mass., March 2, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a GI/Microbiome panel discussion at the Cowen 42nd Annual Health Care Conference, which is taking place virtually on Wednesday March 9, 2022, at 10:30 AM Eastern Time.

Mar 02, 2022 07:35 am ET

Thinking about buying stock in Nordstrom, Indonesia Energy, SoFi Technologies, Ardelyx, or Mullen Automotive?

NEW YORK, March 2, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JWN, INDO, SOFI, ARDX, and MULN.

Feb 28, 2022 03:01 pm ET

Ardelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

WALTHAM, Mass., Feb. 28, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported business events and financial results for the fourth quarter and full year ended December 31, 2021.

Feb 24, 2022 07:00 am ET

Ardelyx Announces $27.5 Million Debt Financing Agreement with SLR Capital Partners

WALTHAM, Mass., Feb. 24, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that it has entered into a debt financing agreement with investment affiliates managed by SLR Capital Partners ("SLR").

Feb 22, 2022 07:00 am ET

Ardelyx to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

WALTHAM, Mass., Feb. 22, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that it will hold a conference call on Monday February 28, at 4:30 pm Eastern Time to discuss fourth quarter and year-end 2021 financial results and provide a corporate update.

Feb 04, 2022 03:01 pm ET

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., Feb. 4, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on February 1, 2022, the compensation committee of the company's board of directors granted four new non-executive employees options to purchase an aggregate of 35,547 shares of the company's common stock, and granted an aggregate of 25,750 Restricted Stock Units (RSUs) to five new non-executive employees. Each stock option has an

Dec 23, 2021 01:01 pm ET

Lifshitz Law Firm, P.C. Announces Investigations of Activision Blizzard, Inc. (NASDAQGS: ATVI), Ardelyx Inc. (NASDAQGM: ARDX), Iterum Therapeutics plc (NASDAQCM: ITRM), and Zymergen Inc. (NASDAQGS: ZY

Activision Blizzard, Inc. (NASDAQGS: ATVI) Lifshitz Law Firm, P.C. announces that a class action complaint was filed against Activision Blizzard alleging Defendants throughout the Class Period, made false and/or misleading statements and/or...

Dec 10, 2021 09:00 pm ET

ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of long-term stockholders following a class action complaint that was filed against Ardelyx on July 30, 2021. Our investigation concerns whether the board of directors of Ardelyx have breached their fiduciary duties to the company.

Dec 10, 2021 09:40 am ET

Thinking about buying stock in Lucid Group, Energy Transfer, Ardelyx, Inspira Technologies, or Arbutus Biopharma?

NEW YORK, Dec. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LCID, ET, ARDX, IINN, and ABUS.

Dec 07, 2021 09:31 am ET

Thinking about buying stock in Gevo, Carnival Corp, Ardelyx, Spirit Realty Capital, or Solid Biosciences?

NEW YORK, Dec. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GEVO, CCL, ARDX, SRC, and SLDB.

Dec 06, 2021 07:30 am ET

Thinking about buying stock in Adicet Bio, GCP Applied Technologies, Aeglea Bio Therapeutics, Fulcrum Therapeutics, or Ardelyx?

NEW YORK, Dec. 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACET, GCP, AGLE, FULC, and ARDX.

Dec 03, 2021 09:50 am ET

Thinking about buying stock in Ardelyx, Celyad Oncology, CSX Corp, American Airlines, or Biolase?

NEW YORK, Dec. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARDX, CYAD, CSX, AAL, and BIOL.

Dec 02, 2021 09:45 am ET

Thinking about buying stock in Ardelyx, American Airlines, DiDi Global, Norwegian Cruise Line, or Express?

NEW YORK, Dec. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARDX, AAL, DIDI, NCLH, and EXPR.

Dec 01, 2021 08:00 am ET

Thinking about buying stock in Applied UV, Ardelyx, VBI Vaccines, Aemetis, or 180 Life Sciences?

NEW YORK, Dec. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AUVI, ARDX, VBIV, AMTX, and ATNF.

Nov 30, 2021 06:00 am ET

Ardelyx Launching IBSRELA® Second Quarter of 2022

FREMONT, Calif. and WALTHAM, Mass., Nov. 30, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialty biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced plans to launch IBSRELA, the company's approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022.

Nov 12, 2021 07:00 am ET

Ardelyx Reports Third Quarter 2021 Financial Results

FREMONT, Calif. and WALTHAM, Mass., Nov. 12, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today reported business events and financial results for the third quarter ended September 30, 2021.

Nov 11, 2021 03:05 pm ET

Ardelyx to Present at the Jefferies London Healthcare Conference

FREMONT, Calif. and WALTHAM, Mass., Nov. 11, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies London Healthcare Conference, which is taking place virtually and in-person on November 16 – 19, 2021. The fireside chat will be available to all registered participa

Nov 05, 2021 09:31 am ET

Thinking about buying stock in Ardelyx, Endo International, Phunware, Canada Goose Holdings, or Nikola Corp?

NEW YORK, Nov. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARDX, ENDP, PHUN, GOOS, and NKLA.

Nov 05, 2021 08:00 am ET

Ardelyx Reports Additional Positive Data Supporting Clinical Utility of Tenapanor at ASN's Kidney Week 2021

FREMONT, Calif. and WALTHAM, Mass., Nov. 5, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced multiple presentations covering additional positive clinical observations with tenapanor at the American Society of Nephrology Kidney Week 2021 (ASN Kidney Week), which is taking place virtually November 4 - November 7, 2021. Ardelyx has completed three successful Phase 3 pivotal trials,

Nov 04, 2021 08:00 am ET

Ardelyx to Pursue Formal Dispute Resolution for Tenapanor

FREMONT, Calif. and WALTHAM, Mass., Nov. 4, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced the company plans to submit a Formal Dispute Resolution Request (FDRR) to appeal the issuance of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the company's New Drug Application (NDA) for tenapanor for the control of serum phosphorus in adult patien

Oct 29, 2021 08:00 am ET

Ardelyx Announces Four Tenapanor Presentations at ASN's Kidney Week 2021

FREMONT, Calif. and WALTHAM, Mass., Oct. 29, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that four tenapanor abstracts have been accepted for presentation at the American Society of Nephrology Kidney Week 2021 (ASN Kidney Week), which is taking place virtually November 4 - November 7, 2021. The accepted abstracts present new observations for tenapanor, a first-in-class phosp

Oct 13, 2021 08:00 am ET

Ardelyx Provides Corporate Update Following Type A Meeting with FDA

FREMONT, Calif. and WALTHAM, Mass., Oct. 13, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that the company has met with the U.S. Food and Drug Administration (FDA) in a Type A meeting, but was not provided sufficient clarity on what constitutes "clinical relevance of the magnitude of treatment effect" and continues to await additional information regarding the path forward fo

Sep 30, 2021 06:27 pm ET

Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for Ardelyx Inc. Investors in Securities Fraud Class Action Lawsuit

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Ardelyx Inc. (NASDAQ: ARDX) (“Ardelyx”) investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Ardelyx securities between August 6, 2020 and July 19, 2021, inclusive (the “Class Period”).

Sep 28, 2021 09:09 am ET

Ardelyx Inc. Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Deadline in Securities Fraud Class Action Lawsuit

RADNOR, Pa., Sept. 28, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of Ardelyx Inc. (NASDAQ: ARDX) ("Ardelyx") that a securities fraud class action lawsuit has been filed against Ardelyx on behalf of those who purchased or acquired Ardelyx securities between August 6, 2020 and July 19, 2021, inclusive (the "Class Period").

Sep 27, 2021 09:15 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ardelyx, SelectQuote, Katapult, and Waterdrop Sciences and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ardelyx, Inc. (NASDAQ: ARDX), SelectQuote, Inc. (NYSE: SLQT), Katapult Holdings,...

Sep 26, 2021 03:15 pm ET

ARDX FINAL DEADLINE TUESDAY: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important September 28 Deadline in Securities Class Action –

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and July 19, 2021, inclusive (the “Class Period”), of the important September 28, 2021 lead...

Sep 24, 2021 11:00 am ET

ARDX Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Ardelyx, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: September 28, 2021

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Sep 24, 2021 09:58 am ET

Investor Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Ardelyx Inc. (ARDX)

The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against Ardelyx Inc. (NASDAQ: ARDX) (“Ardelyx”) on...

Sep 23, 2021 07:20 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadline – ARDX

Pomerantz LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX) and certain of its officers. The class action was filed in the United States District Court for the Northern...

Sep 22, 2021 09:08 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ardelyx, SelectQuote, Katapult, and Waterdrop Sciences and Encourages Investors to Contact the Firm

Sep 22, 2021 05:03 pm ET

ARDX DEADLINE ALERT: ROSEN, A LEADING AND LONGSTANDING LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important September 28 Deadline in Securities Class Action - AR

NEW YORK, Sept. 22, 2021 /PRNewswire/ --

Sep 22, 2021 04:17 pm ET

Scott+Scott Attorneys at Law LLP Reminds Investors of September 28 Deadline in Securities Class Action Against Ardelyx Inc. (NASDAQ: ARDX)

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, reminds investors that a securities class action lawsuit has been filed against Ardelyx Inc. (NASDAQ: ARDX) (“Ardelyx” or the “Company”) and certain of its officers and directors, alleging violatio

Sep 22, 2021 12:10 pm ET

SEPTEMBER 28, 2021 ARDX INVESTOR LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ardelyx,

Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of...

Sep 18, 2021 10:02 am ET

ARDX INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Ardelyx Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Ardelyx Inc. (NASDAQ: ARDX) (“Ardelyx”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California...

Sep 17, 2021 07:15 pm ET

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important September 28 Deadline in Securities Class Action – ARDX

Sep 17, 2021 05:39 pm ET

Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Ardelyx Inc.

RADNOR, Pa., Sept. 17, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against Ardelyx Inc. (NASDAQ: ARDX) ("Ardelyx") on behalf of those who purchased or acquired Ardelyx securities between August 6, 2020 and July 19, 2021, inclusive (the "Class Period").

Sep 15, 2021 09:14 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadline – ARDX

Sep 15, 2021 08:57 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ardelyx, Concho, PayPal, and Cassava Sciences and Encourages Investors to Contact the Firm

Sep 15, 2021 08:15 pm ET

ARDX NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 28 Deadline in Securities Class Action - AR

NEW YORK, Sept. 15, 2021 /PRNewswire/ --

Sep 13, 2021 10:00 am ET

Investor Reminders: ARDX & ATVI Class Actions and Upcoming Deadlines - Bronstein, Gewirtz & Grossman LLC

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...

Sep 10, 2021 08:16 pm ET

Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against Ardelyx Inc.

Sep 10, 2021 07:16 pm ET

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Ardelyx, Inc. (ARDX) Investors and Encourages Investors to Contact the Firm Before Septemb

The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ:

Sep 08, 2021 09:16 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BlueCity, Ardelyx, ATI, and View and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BlueCity Holdings Limited (NASDAQ: BLCT), Ardelyx, Inc. (NASDAQ: ARDX), ATI...

Sep 06, 2021 09:17 pm ET

Kessler Topaz Meltzer & Check, LLP: Reminds Investors of Securities Fraud Class Action Filed Against Ardelyx Inc.

RADNOR, Pa., Sept. 6, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Ardelyx Inc. (NASDAQ: ARDX) ("Ardelyx") on behalf of those who purchased or acquired Ardelyx securities between August 6, 2020 and July 19, 2021, inclusive (the "Class Period").

Sep 06, 2021 01:10 pm ET

ROSEN, A TOP RANKED LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important September 28 Deadline in Securities Class Action – ARDX

Sep 05, 2021 05:20 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadline - ARDX

NEW YORK, Sept. 5, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) and certain of its officers. The class action was filed in the United States District Court for the Northern District of California, Oakland Division, and docketed under 21-cv-06228. Plaintiff brings this federal securities class action under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder, 17 C.F.R. § 240.10b-5, on behalf of a

Sep 03, 2021 04:44 pm ET

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That Securities Class Action Lawsuits Have Been Filed Against Oatly Group AB (OTLY), ATI Physical Therapy, Inc. f/k/a Fortress Value Acquisition C

The law firm of Kirby McInerney LLP reminds investors that securities class action lawsuits have been filed on behalf of stockholders of Oatly Group AB, ATI Physical Therapy, Inc. f/k/a Fortress Value Acquisition Corp. II, and Ardelyx, Inc....

Sep 03, 2021 10:00 am ET

ARDX & ATVI Shareholder Class Actions and Looming Deadlines: Bronstein, Gewirtz & Grossman LLC

Sep 03, 2021 08:50 am ET

Thinking about buying stock in Enveric Biosciences, United Microelectronics, DiDi Global, Aurora Mobile, or Ardelyx?

NEW YORK, Sept. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENVB, UMC, DIDI, JG, and ARDX.

Sep 03, 2021 08:00 am ET

Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial

FREMONT, Calif. and WALTHAM, Mass., Sept. 3, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced the publication of the company's long term 52-week Phase 3 PHREEDOM trial in the American Society of Nephrology journal, Kidney360.

Sep 01, 2021 07:36 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CarLotz, Ardelyx, Activision Blizzard, and SelectQuote and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CarLotz, Inc. (NASDAQ: LOTZ), Ardelyx, Inc. (NASDAQ: ARDX), Activision Blizzard,...

Sep 01, 2021 09:06 am ET

CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Ardelyx Inc. Shareholders of Securities Fraud Class Action Lawsuit

Aug 31, 2021 09:06 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadline – ARDX

Aug 30, 2021 05:52 pm ET

ROSEN, A TOP RANKED LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important September 28 Deadline in Securities Class Action – ARDX

Aug 29, 2021 07:11 pm ET

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Ardelyx Inc.

RADNOR, Pa., Aug. 29, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against Ardelyx Inc. (NASDAQ: ARDX) ("Ardelyx") on behalf of those who purchased or acquired Ardelyx securities between August 6, 2020 and July 19, 2021, inclusive (the "Class Period").

Aug 27, 2021 05:45 pm ET

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ARDX

Aug 27, 2021 03:50 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadline - ARDX

NEW YORK, Aug. 27, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) and certain of its officers. The class action was filed in the United States District Court for the Northern District of California, Oakland Division, and docketed under 21-cv-06228. Plaintiff brings this federal securities class action under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder, 17 C.F.R. § 240.10b-5, on behalf of a

Aug 26, 2021 05:15 pm ET

ARDX NOTICE: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - A

NEW YORK, Aug. 26, 2021 /PRNewswire/ --

Aug 26, 2021 01:09 pm ET

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ardelyx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, Aug. 26, 2021 /PRNewswire/ -- Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Aug 26, 2021 10:12 am ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CarLotz, Ardelyx, Activision Blizzard, and SelectQuote and Encourages Investors to Contact the Firm

Aug 21, 2021 02:12 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadline – ARDX

Aug 21, 2021 11:16 am ET

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against Ardelyx Inc. – ARDX

Aug 19, 2021 09:10 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadline - ARDX

NEW YORK, Aug. 19, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) and certain of its officers. The class action was filed in the United States District Court for the Northern District of California, Oakland Division, and docketed under 21-cv-06228. Plaintiff brings this federal securities class action under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder, 17 C.F.R. § 240.10b-5, on behalf of a c

Aug 19, 2021 04:15 pm ET

ARDX INVESTOR NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – AR

Aug 16, 2021 09:45 pm ET

Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Ardelyx Inc. (ARDX)

RADNOR, Pa., Aug. 16, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against Ardelyx Inc. (NASDAQ: ARDX) ("Ardelyx") on behalf of those who purchased or acquired Ardelyx securities between August 6, 2020 and July 19, 2021, inclusive (the "Class Period").

Aug 13, 2021 07:50 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadline – ARDX

Aug 13, 2021 06:15 pm ET

ARDX INVESTOR NEWS: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ARDX

Aug 13, 2021 10:00 am ET

ARDX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Ardelyx, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) and certain of its officers, on behalf of shareholders who...

Aug 13, 2021 08:00 am ET

Ardelyx Reports Second Quarter 2021 Financial Results

FREMONT, Calif. and WALTHAM, Mass., Aug. 13, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today reported business events and financial results for the second quarter ended June 30, 2021.

Aug 12, 2021 08:25 pm ET

ARDX CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Ardelyx Inc. Shareholders of Securities Fraud Class Action Lawsuit

The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed against Ardelyx Inc. (NASDAQ: ARDX) (“Ardelyx”) on behalf of those who purchased or acquired Ardelyx securities between August 6, 2020 and July 19, 2021, inclusive (the “Class Period”).

Aug 12, 2021 06:10 pm ET

Pomerantz Law Firm Announces the Filing of a Class Action Against Ardelyx, Inc. and Certain Officers - ARDX

NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) and certain of its officers. The class action was filed in the United States District Court for the Northern District of California, Oakland Division, and docketed under 21-cv-06228. Plaintiff brings this federal securities class action under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder, 17 C.F.R. § 240.10b-5, on behalf of

Aug 12, 2021 01:30 pm ET

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Ardelyx, Inc. (ARDX)

Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX) in the United States District Court for the Northern District of California on behalf of those who...

Aug 11, 2021 10:23 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX

NEW YORK, Aug. 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Aug 11, 2021 09:40 pm ET

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

NEW YORK, Aug. 11, 2021 /PRNewswire/ --

Aug 11, 2021 08:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CarLotz, Ardelyx, and Activision Blizzard and Encourages Investors to Contact the Firm

Aug 11, 2021 05:55 pm ET

Ardelyx Inc. Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Ardelyx Inc.

RADNOR, Pa., Aug. 11, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed against Ardelyx Inc. (NASDAQ: ARDX) ("Ardelyx") on behalf of those who purchased or acquired Ardelyx securities between August 6, 2020 and July 19, 2021, inclusive (the "Class Period").

Aug 11, 2021 11:28 am ET

SHAREHOLDER ALERT: Robbins LLP Announces that Ardelyx Inc. (ARDX) is Being Sued for Misleading Shareholders

Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of all purchasers of Ardelyx Inc. securities (NASDAQ: ARDX) between August 6, 2020 and July 19, 2021, for violations of the Securities Exchange Act of 1934. Ardelyx is a biopharmaceutical company that develops medicines for people with cardiorenal disea

Aug 10, 2021 02:13 pm ET

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against Ardelyx Inc. – ARDX

Aug 09, 2021 09:33 am ET

ALERT: Investors with Substantial Losses Have Opportunity to Lead the Ardelyx Inc. Class Action Lawsuit - ARDX

SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Ardelyx Inc. (NASDAQ: ARDX) securities between August 6, 2020 and July 19, 2021, inclusive ("Class Period") have until September 28, 2021 to seek appointment as lead plaintiff in the Ardelyx class action lawsuit. The Ardelyx class action lawsuit charges Ardelyx and certain of its top executives with violations of the Securities Exchange Act of 1934. The Ardelyx class action lawsuit (Strezsak v. Ardelyx Inc., No. 21-cv-05868) was commenced on July 30, 2021 in the Northern District of Cali

Ad blocking detected

Ardelyx, Inc. - Common Stock (OQ:ARDX)

Business Focus: N/A